35 Participants Needed

Evolutionary Tumor Board for Chronic Conditions

MJ
AT
SD
Overseen BySara Donadelli
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new method for creating treatment plans for cancer patients without a cure. The Evolutionary Tumor Board (ETB), a special team, will review each patient's medical history and current treatment options to suggest new strategies. It targets individuals whose previous cancer treatments were not fully effective or whose cancer might recur. Participants should be open to trying new treatment plans and are expected to share their medical data over time. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to explore potentially effective new strategies.

Do I have to stop taking my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that the Evolutionary Tumor Board (ETB) is safe for patients?

Research has shown that the Evolutionary Tumor Board (ETB) approach holds great promise. This method involves experts collaborating to develop new treatment plans for cancer patients with no other options. Since the ETB focuses on planning rather than introducing new drugs or treatments, it does not present direct safety concerns like medication side effects.

However, the safety of any specific treatment suggested by the ETB depends on the treatment itself. The board generates ideas based on each patient's unique situation, so treatment safety can vary. Each proposed treatment has its own safety details based on previous studies or existing approvals.

In summary, participating in a trial with the ETB primarily involves sharing medical history with experts who will devise new treatment strategies. The safety of any specific treatment they recommend must be considered separately, based on that treatment's details.

Why are researchers excited about this trial?

Researchers are excited about the Evolutionary Tumor Board (ETB) because it offers a personalized approach to cancer treatment that differs from traditional methods. Unlike standard treatments that follow a one-size-fits-all model, the ETB examines each patient's clinical history, available therapeutic options, and outcome expectations to devise tailored strategies. This approach leverages evolutionary ideas to adapt treatments, potentially leading to more effective and targeted cancer therapies. By integrating detailed imaging and pathology, the ETB aims to uncover novel therapeutic strategies that could improve patient outcomes.

What evidence suggests that the Evolutionary Tumor Board (ETB) is effective for developing therapeutic strategies in patients without curative options?

Research has shown that the Evolutionary Tumor Board (ETB), which will review participants in this trial, holds promise for improving outcomes in cancer patients. The ETB employs a unique approach by involving experts such as mathematicians and evolutionary biologists to develop better treatment plans. Early results suggest this method can lead to more effective cancer management, particularly when standard treatments have failed. Studies also highlight the ETB's ability to customize treatments to fit each patient's needs, potentially leading to better results. Overall, the ETB represents a promising new approach to addressing challenging cancer cases.12345

Who Is on the Research Team?

JZ

Jingsong Zhang, MD

Principal Investigator

Moffitt Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
Participant must have a life expectancy greater than 3 months
Participant must have an ECOG performance status 0-2
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Review by ETB

Participants' clinical history, available therapeutic options, and outcome expectations are presented to the Evolutionary Tumor Board (ETB) for strategy development

Varies

Follow-up

Participants are monitored for the development and implementation of therapeutic strategies

Up to 60 months

What Are the Treatments Tested in This Trial?

Interventions

  • Evolutionary Tumor Board (ETB)

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Participants Reviewed by ETBExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

H. Lee Moffitt Cancer Center and Research Institute

Lead Sponsor

Trials
576
Recruited
145,000+

Citations

Feasibility of an Evolutionary Tumor Board for Generating ...

We present the concept of an Evolutionary Tumor Board (ETB) and report interim results from a prospective, non-interventional pilot study.

Treatment of evolving cancers will require dynamic decision ...

The ETB integrates the expertise of mathematicians and evolutionary biologists into the clinical decision support framework of a traditional tumor board, and ...

Abstract PR010: Evolutionary Tumor Board: Implementing ...

Early results from the ETB show great promise for improving patient outcomes in cancer using mathematical modeling and evolutionary therapy.

Generating Novel Therapeutic Strategies Based on ...

This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in ...

5.

imoworkshop.org

imoworkshop.org/IMO9/

IMO9: Tumor Board Evolution

The ETB provides guidance on optimal evolution based treatment strategies for individual patients and for the design of clinical trials.